APPLICATION
ANDA065241
TYPE
ANDA
ORIGINAL APPROVAL
2006-07-25
LATEST ACTION
2026-01-18
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
AMPICILLIN AND SULBACTAMPrescription
AMPICILLIN SODIUM EQ 2GM BASE/VIAL, SULBACTAM SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
AMPICILLIN AND SULBACTAMPrescription
AMPICILLIN SODIUM EQ 1GM BASE/VIAL, SULBACTAM SODIUM EQ 500MG BASE/VIAL · INJECTABLE · INJECTION
Approval history
2026-01-18Labeling · Supplement 29 · standardAP
2024-09-27Labeling · Supplement 27 · standardAP
2021-06-21Labeling · Supplement 23 · standardAP
2020-05-14Labeling · Supplement 19 · standardAP
2020-05-14Labeling · Supplement 17 · standardAP
2016-02-19Labeling · Supplement 13 · standardAP
2013-02-22Labeling · Supplement 11 · standardAP
2007-10-31Manufacturing (CMC) · Supplement 3AP
2006-07-25OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.